EMADOC-1700519818-2034703

European Medicines Agency decision

EMA/PE/0000232758

of 14 April 2025

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for remibrutinib in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

EMA/PE/0000232758

of 14 April 2025

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for remibrutinib in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Novartis Europharm Limited on 29 May 2024 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 28 February 2025, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for remibrutinib, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for remibrutinib, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for remibrutinib, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Novartis Europharm Limited, Vista Building, Merrion Road, Elm Park, D04 A9N6 - Dublin 4, Ireland.

EMADOC-1700519818-1820703 Corr[1]
Amsterdam, 28 February 2025

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA/PE/0000232758

Scope of the application

Active substance(s):

Remibrutinib

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of myasthenia gravis

Pharmaceutical form(s):

Film-coated tablet

Age-appropriate oral solid dosage form

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Novartis Europharm Limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Novartis Europharm Limited submitted for agreement to the European Medicines Agency on 29 May 2024 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 8 July 2024.

[1] 12 March 2025

Supplementary information was provided by the applicant on 22 November 2024. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(a) of said Regulation, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of myasthenia gravis

The waiver applies to:

- the paediatric population from birth to less than 6 years of age;
- film-coated tablet, age-appropriate oral solid dosage form, oral use;
- on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric investigation plan

2.1. Condition:

Treatment of myasthenia gravis

2.1.1. Indication(s) targeted by the PIP

Treatment of children 6 years and older with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive (AChR+), anti-muscle-specific tyrosine kinase antibody-positive (MuSK+), or double-seronegative

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Age-appropriate oral solid dosage form

2.1.4. Measures

Area	Description
Quality-related studies	**Study 1** Development of an age-appropriate oral solid dosage form suitable for children from 6 years to less than 12 years of age.
Non-clinical studies	Not applicable.
Clinical studies	**Study 2** Open label, single-arm, uncontrolled trial to evaluate pharmacokinetics, pharmacodynamics, exploratory efficacy and safety of remibrutinib in children from 6 years to less than 18 years of age with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive (AChR+), anti-muscle-

	specific tyrosine kinase antibody-positive (MuSK+), or double-seronegative.
Modelling and simulation analyses	**Study 3** Development of a popPK model based on the PK data from adult patients with gMG and other indications for: • Prediction of initial paediatric dose(s) to be used in Study 2 • use of PopPK(/PD) for PK simulation in children from 6 to less than 18 years of age with gMG as a basis for extrapolation **Study 4** Characterisation of PK and confirmation of the dose to be used in paediatric gMG patients, including update of the model developed in Study 3.
Other studies	Not applicable.
Extrapolation plan	The planned phase III study in adult gMG patients (CLOU064O12301), the paediatric clinical Study 2, Study 3 and Study 4 are part of the extrapolation plan of efficacy data from adults covering the paediatric population from 6 years to less than 18 years of age with gMG. Safety data from paediatric programmes in chronic spontaneous urticaria (CSU) and multiple sclerosis (MS) with remibrutinib available at the time of completion of the paediatric gMG study to be summarized as part of the extrapolation approach.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2033
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.